Sign In
Buy MTSR
$70.50
+0 (+0%)
At Close: Feb 12, 2026
Shareholder Alert: The Ademi Firm investigates whether Metsera Inc. is obtaining a Fair Price for its Public Shareholders
10:00am, Monday, 22'nd Sep 2025
MILWAUKEE , Sept. 22, 2025 /PRNewswire/ -- The Ademi Firm is investigating Metsera (Nasdaq: MTSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Pfizer.
Pfizer acquires Metsera in $7.3B deal to boost obesity drug pipeline
09:49am, Monday, 22'nd Sep 2025
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in c
Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal
09:16am, Monday, 22'nd Sep 2025
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares o
Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera
08:59am, Monday, 22'nd Sep 2025
Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market. The mov
Pfizer makes a $4.9 billion bet on obesity drugs with Metsera buyout deal
08:14am, Monday, 22'nd Sep 2025
Metsera's shareholders could see significant bonuses if certain milestones are reached.
MTSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Metsera, Inc. Is Fair to Shareholders
08:09am, Monday, 22'nd Sep 2025
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Metsera, Inc. (NASDAQ: MTSR) to Pfizer Inc. is fair to Metsera shareholders. Under the te
Nasdaq 100 and S&P500: Intel Weakens, Metsera Spikes 59% on Pfizer Deal, Fed in Spotlight
08:05am, Monday, 22'nd Sep 2025
Dow, S&P500 futures pull back today as Metsera pops 59%, Intel drops, and markets question whether Fed policy will match rate cut forecasts.
Pfizer to Buy Weight-Loss Drug Developer Metsera for Up to $7.3 Billion
07:02am, Monday, 22'nd Sep 2025
Pfizer has agreed to pay up to $7.3 billion for weight-loss drug developer Metsera in a deal that gets the New York drugmaker back into the burgeoning market for obesity drugs.
Pfizer to buy weight-loss drug developer Metsera for up to $4.9 billion
06:54am, Monday, 22'nd Sep 2025
Pfizer said on Monday it would acquire weight-loss drug developer Metsera for up to $4.9 billion to secure its position in the lucrative obesity treatment market.
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
06:45am, Monday, 22'nd Sep 2025
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Metsera, Inc. (NASDAQ: MTSR) today announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a cl
Pfizer closes in on $7.3 billion takeover of anti-obesity drugmaker Metsera, FT reports
12:04am, Monday, 22'nd Sep 2025
Pfizer is closing in on a potential $7.3 billion takeover of anti-obesity drug developer Metsera , the Financial Times reported on Sunday, citing unidentified sources.
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
07:00am, Thursday, 11'th Sep 2025
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases,
